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Abstract
Background: Viscoelastic tests, including thromboelastography (TEG) and rotational thromboelastometry (ROTEM),
provide a global assessment of haemostatic function at the point of care. The use of a TEG or ROTEM system to
guide blood product administration has been shown in some surgical settings to reduce transfusion requirements.
The aim of this review is to evaluate all published evidence regarding viscoelastic testing in the setting of hepatic
surgery.
Methods: We will search MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials databases to
identify randomised controlled trials examining the use of viscoelastic testing for hepatic surgery. Two reviewers
will independently screen titles and abstracts of studies identified and will independently extract data. Any
disagreements will be resolved by discussion with a third reviewer. A meta-analysis will be conducted if feasible.
Discussion: Viscoelastic devices such as TEG and ROTEM are increasingly available to clinicians as a bedside test.
Patients undergoing hepatic surgery have a significant risk of blood loss and coagulopathy requiring transfusion.
Theoretical benefits of use of a TEG or ROTEM system in the hepatic surgical setting include a rationalisation of
blood products, a reduction in transfusion-related side effects, an improvement in patient outcomes including
mortality, and a reduction in cost. This systematic review will summarise the current evidence regarding the use of
viscoelastic testing for hepatic surgery.
Systematic review registration: PROSPERO CRD42016036732
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Background
Thromboelastography (TEG) and rotational thromboe-
lastometry (ROTEM), also known as viscoelastic tests,
are point of care coagulation tests that provide a global
assessment of haemostatic function. Viscoelastic tests
monitor whole-blood coagulation, evaluating clot forma-
tion, strength, and lysis or retraction [1], and are the
only tests that can provide a rapid diagnosis of hyperfi-
brinolysis [2]. Performed at the bedside or in the operat-
ing theatre by clinical staff, TEG and ROTEM are
convenient and provide immediate results.
Point of care coagulation testing allows clinicians to
administer the specific blood products required to replace
deficient components of the coagulation system. TEG- or
ROTEM-guided transfusion algorithms have been shown
to reduce the number of cardiac surgical patients requir-
ing blood transfusion [3]. Viscoelastic testing may also im-
prove blood product management, reduce blood product
transfusion and reduce transfusion-related complications
[4]. These clinical benefits may also be cost beneficial in
select patient groups [5].
Clinical benefit of the use of TEG or ROTEM has been
suggested in settings including cardiac surgery [3, 5],
trauma-induced coagulopathy [6] and post-partum haem-
orrhage [7]. Convincing systematic review of the evidence
is, however, lacking. In a systematic review looking at
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TEG and ROTEM in the context of massive transfusion
in 2013, Afshari et al. found only one eligible trial with a
low risk of bias and concluded that there was an absence
of evidence to assess the effect on morbidity and mortality
[3]. The following year, in the setting of critically ill pa-
tients, Haas et al. found only four small randomised con-
trolled trials [7].
Despite a lack of systematic evidence, there are strong
theoretical arguments for the benefit of TEG and ROTEM.
These arguments have particular strength in the setting of
surgery involving the liver. Despite improvements in surgi-
cal technique, extensive blood loss in liver resections may
still require blood product transfusion, increasing rates of
perioperative morbidity and mortality [8]. Viscoelastic test-
ing, which helps guide transfusion decisions, may lead to
improved patient outcomes including mortality, rationa-
lised use of blood products and reduced cost. This system-
atic review aims to evaluate all published evidence from
randomised controlled trials regarding viscoelastic testing
in the setting of hepatic surgery.
Methods
Objective
The purpose of this study is to systematically review the
current available evidence regarding the use of viscoelas-
tic testing in adults undergoing hepatic surgery.
Protocol and registration
We will follow the methodological standards outlined in
the Cochrane Handbook for Systematic Reviews of Inter-
ventions [9]. The findings will be reported as guided by
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) [10] (also see Additional file 1
‘PRISMA checklist for submission’). The review has been
prospectively registered with the International Prospective
Register of Systematic Reviews (PROSPERO) [11].
Eligibility criteria
Table 1 shows eligibility criteria for population, interven-
tion, comparison and study design. Table 2 shows eligi-
bility criteria for outcomes. We will not apply language
restrictions. Studies will be included independent of
publication status and publication date.
Information sources and search
We will search the following databases: MEDLINE,
EMBASE and the Cochrane Central Register of Con-
trolled Trials databases. The Appendix shows the search
strategy which will be used for each database. References
of all included trials will be scanned for eligibility.
Study selection
Two reviewers (KM and GI) will independently screen
titles and abstracts of studies identified via the search
method as outlined in the Appendix. We will discuss
any discrepancies and will retrieve full copies of all po-
tentially relevant studies. Two reviewers (KM and GI)
will then independently assess the complete publications
for eligibility. Any disagreements will be resolved by dis-
cussion with a third reviewer (DB or EH). We will use
Covidence software to coordinate the study selection
process [12].
Data collection process and data items
Two reviewers will independently extract the data out-
lined below (KM and GI). Any disagreements will be re-
solved by discussion with a third reviewer (DB or EH).
We will contact authors to retrieve any missing data. In
particular, we anticipate finding trials where the popula-
tion is broader than our inclusion criteria but includes pa-
tients undergoing hepatic surgery as a subgroup. When
outcome data for hepatic surgery patients are not pre-
sented for this subgroup in the publication, we will con-
tact authors and attempt to retrieve these data.
For all studies, we will extract the following data:
1. Study characteristics—first author, year of publication,
funding source, study design and setting, duration of
follow-up, number randomised.
2. Population characteristics—inclusion and exclusion
criteria, patient characteristics, underlying disease or
condition (including bleeding diatheses and
anticoagulant/anti-platelet drugs), presence and severity
of liver disease, other co-morbidities, type and duration
of surgery and type of anaesthesia.
Table 1 Eligibility criteria for population, intervention, comparison
and study design










Intervention Use of viscoelastic
testing (TEG or
ROTEM), either alone
or within an algorithm
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3. Intervention characteristics—the type of viscoelastic
test, whether a transfusion algorithm was used,
which transfusion algorithm was used
4. Comparison intervention characteristics—performance
of coagulation studies, or no coagulation testing.
5. Outcomes—as described in Table 2; number
analysed for each outcome, number of drop-outs
with reason. In the case of multi-arm trials, we will
include all arms that fulfil our defined criteria for
the intervention in our intervention arm and all
Table 2 Eligibility criteria for outcomes
Outcome Criteria Data type Planned summary measure
Primary outcome 1. 30-day mortality (all-cause)





Using mortality data in each eligible trial that is >30 days and the longest follow-up
time for that trial
Categorical Relative risk
2. Blood loss (mL)—included if measured from the start of surgery, defined a priori
and measured equally in both groups. We will use follow-up that is closest to including
24 h after the end of surgery.
Numerical Standardised mean difference
Number of participants receiving blood products—included if measured from the start
of surgery, defined a priori and measured equally in both groups. We will use follow-up
that is closest to including 24 h after the end of surgery.
Categorical Relative risk
3. Any type of blood product
4. Autologous red blood cells
5. Any type of autologous coagulation factor
6. Autologous fresh frozen plasma
7. Autologous cryoprecipitate
8. Autologous platelets
Volume of blood products administered—included if measured from the start of surgery,
defined a priori and measured equally in both groups. We will use follow-up that is closest
to including 24 h after the end of surgery.
Numerical Standardised mean difference
9. Red blood cells (mLs or units)
10. Fresh frozen plasma (mLs or units)
11. Cryoprecipitate (mLs or units)
12. Platelets (mLs or units)
Use of other pro-coagulant interventions—included if measured from the start of
surgery, defined a priori and measured equally in both groups. We will use follow-up
that is closest to including 24 h after the end of surgery.
Categorical Relative risk
13. Tranexamic acid
14. Recombinant Factor VIIa
15. Other recombinant factor concentrates
16. Serious complications associated with blood loss and blood product transfusion—
included if measured from the start of surgery, defined a priori and measured equally
in both groups. We will use follow-up that is closest to including 24 h after the
end of surgery.
- Unplanned intensive care unit (ICU) admission <24 h
- Myocardial infarction (MI) <7 days
- Cardiac arrest <24 h
- Central nervous system complications
– Cerebrovascular accident (CVA) or traumatic brain injury (TBI) <7 days post-operation
- renal complications <7 days—where a clear definition of renal complications has been
provided in the paper and measured equally in both groups
Categorical Relative risk
17. Thromboembolic complications—included if measured from the start of surgery,
defined a priori and measured equally in both groups. We will use follow-up that is
closest to including 7 days after the end of surgery.
- New arterial or deep venous thrombosis
- Pulmonary embolism
Categorical Relative risk
18. Cost—we will include any cost outcomes from studies where a numerical
cost outcome has been clearly defined and equally measured for both groups.
Numerical Standardised mean difference
We will include data for the following outcomes if they were specifically measured in both groups and defined a priori
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arms that fulfil our defined criteria for the control in
our control arm.
Risk of bias in individual studies
We will assess the risk of bias according to guidelines in
The Cochrane Handbook of Systematic Reviews [9]. For
each included trial, we will assess selection bias (random
sequence generation and allocation concealment), per-
formance bias (blinding of participants and personnel),
detection bias (blinding of outcome assessment), attri-
tion bias (incomplete outcome data), reporting bias (se-
lective reporting) and any other sources of bias.
When all risk of bias parameters are assessed as satis-
factory, the trial will be categorised as low risk of bias.
Our assessment of low risk of bias will be for the lowest
possible risk. Given that blinding of the testing for the
treating physician is impossible, the lack of this blinding
will not preclude an assessment of satisfactory.
Synthesis of results
We will provide a descriptive synthesis of the findings of
our review. If there are two or more eligible studies,
reporting on the same outcome and with low risk of
bias, meta-analysis will be performed. All testing will be
two-sided. We will assess statistical heterogeneity using
the chi-squared test (Cochran’s Q), the I-squared statis-
tic [13] and diversity (D2) [14]. Irrespective of statistical
estimation of heterogeneity, we will use a random effects
model (Mantel-Haenszel method) [15] to perform the
meta-analyses. A sensitivity analysis will be performed
using a fixed effect model, and we will report any rele-
vant differences. Continuity correction will be used for
zero event trials [16].
The risk of random errors, caused by sparse data and re-
petitive testing, will be assessed using Trial Sequential
Analysis (TSA) [14, 17–19]. We will estimate a diversity-
adjusted required information size [14] using 0.05 for type
1 error, 0.2 for type 2 error, control event proportions esti-
mated from the un-weighted mean of the proportions in
the control groups in the included trials and a relative risk
reduction (RRR) of 20 %. Additional sensitivity analyses
will be conducted for each TSA using the empirical RRR
to estimate effect size.
We will use Review Manager software for the conven-
tional meta-analyses [20]. TSA software will be used for the
TSA [21]. We will use R statistical software for any other
analyses or calculations required [22], and all code will be
published to ensure reproducibility of all our analyses.
Subgroup analysis
For our primary outcome, mortality, and for our secondary
outcomes, our first analyses will include all populations of
patients undergoing hepatic surgery.
When possible, we will then conduct two subgroup
analyses based on hepatic surgery types:
1. Elective operations involving hepatic resection
2. Hepatic transplantation
For each of the above analyses, when possible, we will
do two further subgroup analyses based on population:
1. Severe hepatic failure
2. Pre-existing coagulopathy
We will accept any reasonable definitions for the above
subgroups provided by the individual trials, as long as they
have been clearly defined a priori and where the outcomes
have been measured in these subgroups equally in both
arms of the trial.
Risk of bias across studies
If more than 10 trials are included in the cumulative
meta-analyses, we will assess the risk of publication bias
by Funnel plots and Egger’s/Begg’s test [23].
Grading the quality of the evidence
We will consider the quality of the evidence using the
GRADE Working Group’s guidelines [24]. We will provide
a summary of the evidence, based on the GRADE format,
for every outcome that we meta-analyse. For each included
outcome, we will consider the risk of bias in included trials,
the risk of publication bias, the precision, the consistency
and the directness.
Discussion
As the technology simplifies and becomes more cost-
effective, viscoelastic devices such as TEG and ROTEM
are increasingly available to clinicians as a bedside test.
The most recent incarnations of both systems, the TEG6s
and the ROTEM Sigma, are portable and easy to use, with
reduced blood handling compared with previous systems
[25, 26]. These systems are point-of-care, producing a
shorter turnaround time compared with traditional coagu-
lation testing.
Arguably, the most significant advantage over trad-
itional testing is that viscoelastic tests evaluate the func-
tion rather than the quantity of individual haemostatic
factors [27]. By recording the process of clot formation
as a trace, both TEG and ROTEM display parameters that
indicate the need for specific corrective blood components
[1]. During haemorrhage with resulting coagulopathy, these
results can be used to guide an individualised and timely
response.
Due to an increased risk of preoperative coagulopathy
associated with liver dysfunction and to the surgical risks
associated with surgery involving the liver, patients
McCrossin et al. Systematic Reviews  (2016) 5:151 Page 4 of 7
undergoing hepatic surgery have a significant risk of
perioperative blood loss and coagulopathy requiring
transfusion. Functional coagulation in the presence of liver
disease can be poorly predicted by conventional coagula-
tion testing [28]. TEG and ROTEM may therefore offer
particular advantages for this patient population, by allow-
ing more timely and potentially more accurate decisions
about whether to give coagulation products and which to
give. These decisions may result in better clinical out-
comes, including mortality. With more timely and targeted
treatment of coagulopathy in the setting of hepatic sur-
gery, blood loss may be reduced, avoiding both the adverse
clinical outcomes associated with blood loss itself and with
red cell transfusion [29]. Moreover, timing and targeted
treatment of coagulopathy may also be associated with a
reduced use of coagulation products themselves, also lead-
ing to a reduction in the adverse clinical outcomes associ-
ated with these transfusions. If the use of ROTEM or TEG
in the setting of hepatic surgery does lead to a reduction
in transfusion, and is associated with improved clinical
outcomes, the potential cost benefit of using these tests
represents a further important advantage.
We aim to systematically examine the effects of TEG
or ROTEM in the setting of hepatic surgery. The
Cochrane Handbook recommends considering inclusion
of clinically important outcomes as primary in a system-
atic review, such as all-cause mortality [9]. In the case of
TEG and ROTEM in the setting of hepatic surgery, the
important clinical question is how do these tests, in as-
sociation with whatever clinical intervention results from
using them, alter clinical outcomes. This systematic re-
view will summarise the available evidence regarding the
use of viscoelastic testing for hepatic surgery, focusing
on mortality as a primary outcome and also exploring
the effect on blood loss, blood product use, adverse ef-
fects of blood loss and transfusion, and cost.
Appendix
Search strategies
Search strategies finalised 24/6/16
Medline (Ovid)
1. exp Liver/
2. (hepatic or liver or hepato*).mp.
3. 1 or 2
4. exp General Surgery/
5. (surger* or surgical* or reconstruct* or resection* or
segment* or transplant*).mp.
6. exp Anesthesia, General/
7. (anaesthesia or anesthesia).mp.
8. 4 or 5 or 6 or 7
9. 3 and 8
10. “blood transfusion*”.mp.
11. hemorrhage*.mp.
12. exp Carcinoma, Hepatocellular/su [Surgery]





18. exp Liver Transplantation/
19.“liver transplant*”.mp.
20. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19







28. ((“point of care” or POC or POCT or test* or
function* or therap* or analys*) adj4 coag*).mp.
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 20 and 29
31. randomized controlled trial.pt.






38. 31 or 32 or 33 or 34 or 35 or 36 or 37
39. 30 and 38
40. (animals not (humans and animals)).sh.
41. 39 not 40
Embase (Ovid)
1. Exp Liver
2. (hepatic or liver or hepato*).mp.
3. 1 or 2
4. exp general surgery/
5. (surger* or surgical* or reconstruct* or resection* or
segment* or transplant*).mp.
6. exp general anesthesia/
7. (anaesthesia or anesthesia).mp.
8. 4 or 5 or 6 or 7
9. 3 and 8
10. “blood transfusion*”.mp.
11. hemorrhage*.mp.
12. exp liver cell carcinoma/su [Surgery]
13. exp liver tumor/su [Surgery]




18. exp liver transplantation/
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19. “liver transplant*”.mp.
20. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19







28. ((“point of care” or POC or POCT or test* or
function* or therap* or analys*) adj4 coag*).mp.
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. 20 and 29
31. randomized controlled trial.pt.






38. 31 or 32 or 33 or 34 or 35 or 36 or 37
39. animals/ not humans/
40. 38 not 39
41. 30 and 40
Cochrane
1. MeSH descriptor: [Liver] explode all trees
2. hepatic or liver or hepato*:ti,ab,kw (Word variations
have been searched)
3. #1 or #2
4. MeSH descriptor: [General Surgery] explode all trees
5. surger* or surgical* or reconstruct* or resection* or
segment* or transplant*:ti,ab,kw (Word variations
have been searched)
6. MeSH descriptor: [Anesthesia, General] explode all
trees
7. anaesthesia or anesthesia:ti,ab,kw (Word variations
have been searched)
8. 4 or 5 or 6 or 7
9. #3 and #8
10. “blood transfusion*”:ti,ab,kw (Word variations have
been searched)
11. hemorrhage*:ti,ab,kw (Word variations have been
searched)
12.MeSH descriptor: [Carcinoma, Hepatocellular]
explode all trees and with qualifier(s):
[Surgery – SU]
13.MeSH descriptor: [Liver Neoplasms] explode all
trees and with qualifier(s): [Surgery – SU]
14.MeSH descriptor: [Hepatectomy] explode all trees
15.Hepatectom*:ti,ab,kw (Word variations have been
searched)
16. “hemi hepatectom*:ti,ab,kw (Word variations have
been searched)
17. hemi-hepatectom*:ti,ab,kw (Word variations have
been searched)
18.MeSH descriptor: [Liver Transplantation] explode
all trees
19. “liver transplant*:ti,ab,kw (Word variations have
been searched)
20. #9 or #10 or #11 or #12 or #13 or #14 or #15 or
#16 or #17 or #18 or #19
21.Viscoelastic near/3 (test* or device* or
method*):ti,ab,kw (Word variations have been
searched)
22.Thromboelasto* or thrombelasto*:ti,ab,kw (Word
variations have been searched)
23.Thromb?elastograph*:ti,ab,kw (Word variations
have been searched)
24.TEG:ti,ab,kw (Word variations have been searched)
25. ROTEM:ti,ab,kw (Word variations have been
searched)
26. (“point of care” or POC or POCT or test* or function*
or therap* or analys*) near/4 coag*:ti,ab,kw (Word
variations have been searched)
27. #21 or #22 or #23 or #24 or #25 or #26
28. 20 and 27
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